ReviewMolecules (Basel, Switzerland)2025
Cyclophane-Based Dendrimers: Today and Tomorrow.
Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PAMAM dendrimers as efficient drug nanocarriers of natural compounds in breast cancer therapeutics.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
For decades, dendrimers have attracted the great interest of researchers, and continue to do so to this day. These compounds found a wide variety of applications in such areas as medicine, catalysis, and electronics. However, their synthesis is very expensive, and purification and isolation are difficult. In addition, dendrimers are often highly toxic. Toxic properties are significantly dependent on the generation and terminal group features. For the toxicity, decreasing the modification of dendrimer structure is widely used. This review discusses some examples of constructing dendrimers based on macrocyclic compounds-cyclophanes (pillararenes, resorcinarenes, and (thia)calixarenes). Preparation of these hybrids is not very difficult, and due to the presence of a hydrophobic macrocyclic platform, they acquire a number of practically useful properties that are not available to traditional dendrimers, such as additional opportunities for encapsulating substrates. Moreover, dendrimers acquire amphiphilic and chiral properties. This review is devoted to the features of the synthesis and properties of macrocyclic dendrimers based on cyclophanes. The review also demonstrates the prospects of using the resulting dendrimers for medicine, sensorics, catalysis and alternative energy sources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.